1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Mauna Kea Technologies S.A.

Mauna Kea Technologies S.A.

ALMKT.PA
Mauna Kea Technologies S.A.undefined flagEuronext Paris
0.16
EUR
+0.00
- -
14.47MMarket Cap
Mauna Kea Technologies S.A.
ALMKT.PA
(Euronext Paris)

Recent

price

0.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.11
0.45
0.66
0.73
0.79
0.57
0.5
0.32
0.27
0.29
0.21
0.2
0.17
0.21
0.12
0.09
Revenue per Share
-0.11
-0.71
-0.97
-0.84
-1
-0.84
-0.55
-0.49
-0.51
-0.61
-0.42
-0.35
-0.25
-0.08
-0.16
0.12
Basic EPS, GAAP
-0.1
-0.65
-1.08
-0.78
-0.96
-0.8
-0.47
-0.5
-0.48
-0.46
-0.3
-0.3
-0.2
-0.02
-0.1
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.1
-0.66
-0.93
-0.8
-0.96
-0.8
-0.51
-0.44
-0.47
-0.56
-0.38
-0.31
-0.21
-0.03
-0.12
0.2
Book Value per Share
0.14
4.41
2.75
1.93
1.05
0.73
0.49
0.69
0.24
-0.08
-0.5
-0.36
-0.51
-0.39
-0.4
-0.07
Tangible Book Value per Share
35
11
13
14
14
15
18
21
25
25
31
38
45
49
64
88
Basic Weighted Avg Shares
4
5
9
10
11
9
9
7
7
7
7
8
7
10
8
8
Sales/Revenue/Turnover
-98.56
-161.56
-150.25
-115.48
-125.3
-151.61
-113.69
-145.18
-177.44
-175.32
-183.25
-147.68
-11.99
-54.27
-79.02
-63.18
Operating Margin (%)
- -
1
1
1
1
1
1
1
1
1
1
2
1
2
2
1
Depreciation Expense
-4
-8
-13
-12
-14
-13
-10
-10
-13
-15
-13
-13
-11
-4
-10
11
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-96.12
-157.68
-148.2
-115.43
-126.84
-147.92
-110.89
-153.21
-189.13
-205.52
-196
-174.61
-149.49
-35.56
-135.91
130.99
Profit Margin (%)
7
51
39
29
17
13
10
20
11
10
8
11
2
-12
-24
6
Working Capital
2
3
2
3
3
2
3
7
6
15
26
27
27
13
7
12
LT Debt
7
52
40
30
18
14
11
17
8
- -
-12
-10
-20
-17
-24
-5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-496.74%
5.21%
-80.24%
Free Cash Flow
33.68%
70.51%
-40.5%
Net Income, GAAP
-9.26%
-20.56%
-203.55%
Sales/Revenue/Turnover
1.35%
7.14%
7.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
10
2024
- -
- -
- -
- -
8
2025
- -
- -
- -
- -
8

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.08
2024
- -
- -
- -
- -
-0.16
2025
- -
- -
- -
- -
0.12

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Second Sight Medical Products, Inc. (EYES)
CardieX Limited (CDX.AX)
Elbit Medical Technologies Ltd (EMTC-M.TA)
Shanghai General Healthy Information and Technology Co., Ltd. (605186.SS)
Imagin Medical Inc. (IME.CN)
Kubota Pharmaceutical Holdings Co., Ltd. (KBBTF)
Business
Mauna Kea Technologies S.A. (Euronext Growth: ALMKT) develops and commercializes Cellvizio, a real-time in vivo cellular imaging platform based on probe and needle-based confocal laser endomicroscopy (p/nCLE) technology; the platform includes Confocal Miniprobes inserted into standard endoscopes for cellular visualization in gastroenterology, interventional pulmonology, neurosurgery, urology, and uro-oncology; it supports applications such as accelerating cancer diagnosis, informing treatment decisions, improving surgical margins, and addressing food intolerances via the CellTolerance brand with a pay-per-use model in ambulatory surgery centers. Founded in 2000 and headquartered in Paris, France, the company operates globally with over 100,000 patient procedures performed, FDA clearances, CE marks, and Category 1 CPT codes; it targets physicians, hospitals, and drug developers in Europe, the United States, and Asia, with key partnerships including Johnson & Johnson, Telix Pharmaceuticals, and an exclusive U.S. commercialization alliance with TaeWoong Medical USA for pancreatic cyst management announced in December 2025. Recent developments encompass receipt of NMPA regulatory approval in China for the next-generation Cellvizio Gen 3 platform in November 2025; successful completion of a €6.1 million capital raise and exit from safeguard proceedings in November 2025 with strong backing from Vester Finance; launch of CellTolerance in Q4 2024 yielding a pipeline of over 40 commercial opportunities and €0.5 million in 2024 revenue targeting threefold growth in 2025; engagement of investment banks RM Global and Bucephale Finance since November 2024 to explore strategic options including M&A and licensing deals; and evaluation of options for its China joint venture with Tasly Pharmaceutical amid limited commercialization progress.